Susquehanna International Group
JUNO

Susquehanna International Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Susquehanna International Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-615,700
Closed -$28.1M – 10808
2017
Q4 		$28.1M Buy
615,700
+95,600
+18% +$4.77M 0.01% 1016
2017
Q3 		$23.3M Buy
520,100
+103,200
+25% +$3.52M 0.01% 1114
2017
Q2 		$12.5M Sell
416,900
-57,500
-12% -$1.42M 0.01% 1531
2017
Q1 		$10.5M Sell
474,400
-428,700
-47% -$9.2M 0.01% 1582
2016
Q4 		$17M Buy
903,100
+209,800
+30% +$5.13M 0.01% 1163
2016
Q3 		$20.8M Buy
693,300
+193,200
+39% +$6.01M 0.01% 989
2016
Q2 		$19.2M Buy
500,100
+153,800
+44% +$6.38M 0.01% 1003
2016
Q1 		$13.2M Sell
346,300
-38,400
-10% -$1.34M 0.01% 1302
2015
Q4 		$16.9M Sell
384,700
-297,500
-44% -$14.8M 0.01% 1262
2015
Q3 		$27.8M Buy
682,200
+293,000
+75% +$12.9M 0.01% 965
2015
Q2 		$20.8M Buy
389,200
+200,900
+107% +$10.7M 0.01% 1271
2015
Q1 		$11.4M Buy
+188,300
New +$9.14M 0.01% 1747

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Susquehanna International Group's JUNO Position: Q1 2018 in Review

Susquehanna International Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 352,027 shares — an estimated $16.1M sold.

Susquehanna International Group first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $16.1M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Susquehanna International Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Susquehanna International Group sold 352,027 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $16.1M.
  • Susquehanna International Group first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Susquehanna International Group's Juno Therapeutics, Inc. position peaked at $16.1M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Susquehanna International Group's 13F filing for Q1 2018, filed 15 May 2018.